ArticleScience translational medicine2018
High-throughput sequencing of the T cell receptor β gene identifies aggressive early-stage mycosis fungoides.
Abstract read
In one paragraph
Article in Science translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed.
- Next-generation sequencing-based monitoring of circulating tumor DNA reveals clonotypic heterogeneity in untreated PTCL.Blood advances · 2021Trial
- Evaluation of Low-Dose, Low-Frequency Oral Psoralen-UV-A Treatment With or Without Maintenance on Early-Stage Mycosis Fungoides: A Randomized Clinical Trial.JAMA dermatology · 2019Trial
- Review
- T-cell receptor gamma (TRG) diversity predicts peripheral blood involvement in primary cutaneous T-cell lymphoma.Blood neoplasia · 2026Article
- Molecular Markers Distinguishing Early-Stage Mycosis Fungoides From Atopic Dermatitis Skin Lesions.Experimental dermatology · 2026Article
- Chemokine Networks in Cutaneous T Cell Lymphoma: Tumor Microenvironment Remodeling and Therapeutic Targets.Current issues in molecular biology · 2026Review
- A digital polymerase chain reaction method targeting non-recombined T-cell receptor sequences aids in diagnosing primary cutaneous T-cell lymphomas.Journal of Cancer · 2026Article
- Epigenetic dysregulation in mycosis fungoides and sézary syndrome.Frontiers in cell and developmental biology · 2026Review
- Established and emerging prognostic factors in mycosis fungoides and Sézary syndrome.Frontiers in oncology · 2026Review
- Prognosis of increasing percentages of lesional body surface area in early stage mycosis fungoides.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- T-Cell Receptor Clonotypes and Aggressive Subtypes in Cutaneous T-Cell Lymphoma.JAMA dermatology · 2026Article
- Immune control of functional memory CD8 T cells in normal-appearing vitiligo skin.Science advances · 2025Article
- High-Throughput Sequencing and Estimated Relapse Risk in Patients With Sézary Syndrome.JAMA dermatology · 2025Article
- The diagnosis of early-stage mycosis fungoides: Views held by experts and non-experts in cutaneous lymphoma.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025Article
- Dermatopathological Challenges in Objectively Characterizing Immunotherapy Response in Mycosis Fungoides.Dermatopathology (Basel, Switzerland) · 2025Review
- T Cell Repertoire Analysis as a Molecular Signature of the Spectrum of T-LGL Lymphoproliferative Disorders: Tracing the Literature.Current issues in molecular biology · 2025Review
- Article
- Oligoclonality of TRBC1 and TRBC2 in T cell lymphomas as mechanism of primary resistance to TRBC-directed CAR T cell therapies.Nature communications · 2025Article
- The Future of TCR-like Antibodies in Diagnosis and Potential Application Targets.Current molecular medicine · 2025Review
- Nanopore Sequencing for T-Cell Receptor Rearrangement Analysis in Cutaneous T-Cell Lymphoma.Cancers · 2024Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Adele de MassonDepartment of Dermatology, Brigham and Women's Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0001-7828-6211
John T O'MalleyDepartment of Dermatology, Brigham and Women's Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-9968-1517
Christopher P ElcoDepartment of Dermatology, Brigham and Women's Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA 02115, USA.
Sarah S GarciaDepartment of Dermatology, Brigham and Women's Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA 02115, USA.
Sherrie J DivitoDepartment of Dermatology, Brigham and Women's Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-9148-8691
Elizabeth L LowryDepartment of Dermatology, Brigham and Women's Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0001-7892-608X
Marianne TawaDepartment of Dermatology, Brigham and Women's Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA 02115, USA.
David C FisherCenter for Hematologic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
Phillip M DevlinDepartment of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA 02115, USA.
Jessica E TeagueDepartment of Dermatology, Brigham and Women's Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA 02115, USA.
Nicole R LeboeufDepartment of Dermatology, Brigham and Women's Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA 02115, USA.
Ilan R KirschAdaptive Biotechnologies, Seattle, WA 98102, USA.
Harlan RobinsAdaptive Biotechnologies, Seattle, WA 98102, USA.ORCID 0000-0001-5225-7076
Rachael A ClarkDepartment of Dermatology, Brigham and Women's Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA 02115, USA. tkupper@bwh.harvard.edu rclark@bwh.harvard.edu.ORCID 0000-0002-6105-5764
Thomas S KupperDepartment of Dermatology, Brigham and Women's Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA 02115, USA. tkupper@bwh.harvard.edu rclark@bwh.harvard.edu.ORCID 0000-0002-4229-2916
Funding
Harvard Clinical and Translational Science CenterUL1TR001102 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2013 to 2017
$106.2MTargeting Raf in Melanoma: Mechanisms for Effect & Resistance & Opportunities forP50CA093683 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI GOLUB, TODD R. · 2001 to 2012
$25.8MThe Next Generation Immunoanalysis CoreP30AR069625 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI CLARK, RACHAEL ANN · 2016 to 2025
$8.8MDERMATOLOGY TRAINING GRANTT32AR007098 · NIAMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI THOMAS S. KUPPER · 1986 to 2026
$8.1MSkin Homing T CellsR01AR065807 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI KUPPER, THOMAS S. · 2013 to 2022
$6.3MTransforming the diagnosis and care of patients with CTCL using TCR sequencingR01CA203721 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI CLARK, RACHAEL ANN, KUPPER, THOMAS S. · 2016 to 2020
$3.4MInvestigating a novel cell population in delayed-onset drug hypersensitivity reactionsDP5OD023091 · OD · BRIGHAM AND WOMEN'S HOSPITAL · PI DIVITO, SHERRIE JILL · 2016 to 2020
$2.1MCTCL immunobiology: lessons from alemtuzumabR01AR063962 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI CLARK, RACHAEL ANN · 2013 to 2017
$1.8MNCATS NIH HHS UL1 TR001102NCI NIH HHS P50 CA093683NCI NIH HHS R01 CA203721NIAMS NIH HHS P30 AR069625NIAMS NIH HHS R01 AR063962NIAMS NIH HHS R01 AR065807NIAMS NIH HHS T32 AR007098NIH HHS DP5 OD023091
Abstract
Mycosis fungoides (MF), the most common cutaneous T cell lymphoma (CTCL) is a malignancy of skin-tropic memory T cells. Most MF cases present as early stage (stage I A/B, limited to the skin), and these patients typically have a chronic, indolent clinical course. However, a small subset of early-stage cases develop progressive and fatal disease. Because outcomes can be so different, early identification of this high-risk population is an urgent unmet clinical need. We evaluated the use of next-generation high-throughput DNA sequencing of the T cell receptor β gene (
Indexed as
Genes, T-Cell Receptor betaCellular MicroenvironmentClone CellsExomeFemaleGene Expression Regulation, NeoplasticHigh-Throughput Nucleotide SequencingHumansLymphoma, T-Cell, CutaneousMaleMiddle AgedMultivariate AnalysisMycosis FungoidesPrognosisProgression-Free SurvivalSkin
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.